SRX Global Inc. completed a secured financing transaction with CERo Therapeutics Holdings, Inc., issuing a Consolidated Senior Secured Promissory Note aggregating $5,666,108.77 to consolidate previous convertible notes. The agreement allows for additional advances up to $6,000,000, bringing the maximum loan facility to $11,666,108.77. An initial advance of $775,665.00 was funded on August 27, 2026, with monthly funding scheduled thereafter based on CERO's budget. The debt bears interest at 10% per annum and matures on October 15, 2026, secured by CERO’s subsidiary stock and assets. SRX Global Inc. operates as an AI-enabled investment platform focused on generating shareholder value through strategic investments in operating companies.
